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INTRODUCTION
Molecular taxonomy of ovarian cancer suggests several key 
players in each of its subtypes: p53 in serous type; non-p53 
pathways, including K-RAS, in mucinous type; and phospha-
tase and tensin homolog (PTEN) in endometrioid tumors.1 Re-
cently, another key molecule of ovarian cancer progression 
has been found, AT-rich DNA-interacting domain 1A (ARID1A), 
in clear cell carcinoma of ovary (O-CCC).2-4 ARID1A encodes 
BAF250a protein, which is one of the largest subunits of the hu-
man SWI/SNF chromatin-remodeling complex that functions 
actively in histone deacetylation and DNA methylation,5 and 
many of the complex components are identified as tumor sup-
pressors.6 ARID1A participates in cell cycle arrest by regulating 
c-myc.7 In O-CCC, ARID1A mutation and loss is frequent, which 
seems to work as a tumor suppressor.2 Loss of this protein has 
also been found in atypical endometriosis,8 which can trans-
form directly to O-CCC,9,10 also implying a role in the early stag-
es of carcinogenesis.11
The functional consequences of ARID1A loss in O-CCC are 
not yet clear. In normal conditions, ARID1A is necessary for 
SWI/SNF complexes to respond to upstream steroid hormone 
receptor signaling, such as glucocorticoid, estrogen, and andro-
gen receptors.12 Interestingly, among those steroid hormone re-
ceptors, estrogen receptor beta (ERβ) expressional loss is also 
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noted in ovarian cancers,13 which may also be involved in ARI-
D1A loss-dependent O-CCC pathophysiology. Of its down-
stream signaling, SWI/SNF complex regulates cell adhesion 
proteins CD44 and E-cadherin.14 Thereby, loss of CD44 and/or 
E-cadherin could be a sign that ARID1A loss-dependent carci-
nogenic process is activated. 
Overexpression of HNF1β is another recently found O-CCC 
molecular feature. Positive expression of HNF1β is noted in 90–
95% of O-CCCs, contrary to less than 10% of positivity in other 
epithelium-origin ovarian cancers.15 HNF1β seems to work in 
the maintenance of E-cadherin expressing epithelial pheno-
type of O-CCC16 and, thereby, associated with good prognosis.17 
However, the functional implications of HNF1β overexpression, 
particularly in relation to ARID1A loss in O-CCC pathophysiol-
ogy, have yet to be determined.
O-CCC is often resistant to therapies. If found at an early 
stage, it can be effectively managed by oophorectomy.18 In con-
trast, advanced O-CCCs exhibit heterogeneous behavior, being 
unpredictable with known clinic-pathological information, 
such as tumor grade, histologic subtype, stage, etc.19 In this sit-
uation, the expressional status of ARID1A and other biomark-
ers, including ER β, E-cadherin, and HNFβ, may provide further 
prognostic values.17,20 In this study, we analyzed the molecular 
profiles and prognostic factors of O-CCC, focusing on the dif-
ferent clinical and molecular characteristics of ARID1A-posi-
tive and ARID1A-negative tumors.
MATERIALS AND METHODS
Patients
The study subjects were patients diagnosed with O-CCC at 
Severance Hospital. Medical charts were retrospectively re-
viewed to compare clinicopathological features including prog-
nosis. For 87 patients from the Yonsei University Health System 
archived files, O-CCC diagnoses were confirmed in the past 5 
years. All of the tumors were examined retrospectively by 
double-blind test for accuracy of histological subtyping and 
grading. With exclusion of ambiguous histology or inappropri-
ate immunoprofiles, 70 were eligible for this study (29–67 years 
of age, median 49 years of age). Four cases with mixed sub-
types (endometrioid carcinoma and serous carcinoma), and 
thirteen cases with an incompatible and distinct immunopro-
file were excluded. All of the patients provided written in-
formed consent, and the Research Ethics Board Committee of 
Yonsei University Health Medicine approved the study. Evalu-
Fig. 1. Histologic grades of O-CCC. (A and B) Low grade O-CCC. (A) tubulocystic or alveolar patterns are the most common patterns seen in low grade 
tumor. Abortive small tubules are less differentiated (H-E, ×100). (B) Psammomatous calcifications (H-E, ×100). (C and D) High grade O-CCC. (C) Dif-
fuse, solid areas are frequently seen in high grade tumor. Desmoplasia is frequently found in association with infiltrative cells (H-E, ×40). (D) highly 
cellular spindle cells are parallel with infiltrating tumor cells (H-E, ×200). O-CCC, clear cell carcinoma of ovary; H-E, hematoxylin-eosin.
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ated parameters included patient age, parity, follow-up peri-
ods, tumor size and FIGO stage,21 associated pathology (endo-
metriosis and adenofibroma), histologic grade, and oncologic 
outcomes (disease recurrence, distant metastasis, and cancer-
related death). Histologic grade was based on cellular atypia 
and mitotic indices of the major parts of the tumors. Low grade 
was defined as minimal or no atypia in focal areas less than one 
high-powered field (HPF), a low mitotic index (MI) less than 
5/10 HPF, and/or primarily tubular or papillary patterns (Fig. 
1A and B), whereas high grade was defined as severe atypia in 
multifocal areas more than one HPF, a high MI more than 5/10 
HPF, and/or a primarily solid pattern (Fig. 1C and D).
Immunohistochemistry using tissue microarray 
preparation and interpretation
Macroscopic inspection of whole mount tumor sections was 
performed to determine whether they were homogeneous or 
heterogeneous in nature. A core needle was used to make 2-mm 
holes in recipient blocks. Based on prior inspection, three adja-
cent areas of ovarian carcinomas from matching donor blocks 
were transplanted into recipient blocks using a 2-mm core nee-
dle. The 4-μm tissue sections were placed on silane-coated 
slides, deparaffinized, immersed in phosphate-buffered saline 
containing 0.3% (v/v) hydrogen peroxide, and processed in a 
microwave oven for 15 min at 700 W in 10 mM sodium citrate 
buffer (pH 6.5). After blocking for 30 min with 1% (w/v) bovine 
serum albumin, sections were incubated for 16 h at 4°C with 
biotin-labeled rabbit antibodies. The primary antibodies includ-
ed ARID1A (C-terminal, 1:50, Abcam, Cambridge, MA, USA), 
HNF1β (SPA002083, 1:400, Sigma-Aldrich, St. Louis, MI, USA), 
p53 (DO-7, 1:100, Dako, Santa Clara, CA, USA), p38 (Phospho 
T180+Y182, 1:100, Abcam, Cambridge, MA, USA), E-cadherin 
(H-108, 1:200, Santa Cruz, Dallas, TX, USA), ERβ (1:50, Protein-
tech, Rosemonta, IL, USA), and Survivin (EP2880 1:100, Abcam, 
Cambridge, MA, USA). Streptavidin-conjugated peroxidase was 
used as the secondary antibody (1:10000). Normal goat serum 
and subtype-matched normal mouse IgG were used as negative 
controls. The final reaction product was visualized upon the 
addition of 0.03% (w/v) of 3, 3’-diaminobenzidine tetrachloride 
(DAB) for 5 to 20 min.
ARID1A1 expression was interpreted as “loss” if less than 5% 
of the tumor cells showed nuclear staining. If staining was 
modest (between 5% and 50% of the tumor cells), expression 
was interpreted as “focal loss.” When more than 50% of the cells 
were positive, ARID1A was evaluated as “intact.” For HNF1β ex-
pressions, two-tiered grading was applied: grade 1 in patch stain-
ing (focal loss) or grade 2 for diffuse and strong expression. ERβ 
expressions were graded from 0 to 3+ according to the Ameri-
can Society of Clinical Oncology/College of American Pathol-
ogists (ASCO/CAP) guidelines and grade 1, 2, and 3 were con-
sidered “positive” (2). E-cadherin membrane staining was 
graded as grade 0, indicating diffuse loss of more than 10%; 
grade 1, indicating focal loss of less than 10%; and grade 2, indi-
cating no loss. All of the antibodies were initially applied to 
whole slides followed by tissue microarray.
Statistical analyses
Demographic data were analyzed using the parametric, inde-
pendent two-sample t-test and the chi-square (or Fisher’s ex-
act test) for continuous and categorical variables, respectively. 
Categorical variables are reported as frequencies, and continu-
ous variables are reported as means±standard deviations. To 
compare cancer-specific survival, Kaplan-Meier survival curves 
were generated for ARID1A-positive and negative tumors. Mean 
survival times of ARIDA-positive and negative tumors were 
compared by using log-rank test. All p-values <0.05 were con-
sidered to be statistically significant. All analyses were per-
formed with SAS (version 9.2, SAS Institute Inc., Cary, NC, USA) 
and R statistical software (version 3.1.1, www. R-project.org).
RESULTS
Table 1 summarizes patient characteristics. Tumors that were 
removed were of variable sizes ranging from 2–25 cm (median 
8 cm). The majority of tumors were low stage [stage I: 36 (52%); 
stage II: 5 (7%)] (Table 1). Mean follow-up period were 40±36 
months. The numbers of recurrences, metastasis, and deaths 
due to disease were 4 (3%), 19 (13%), and 10 (14%) cases, re-
spectively. 
Table 1. Patient Characteristics
No. (%)
Age, mean±SD, yrs 48.4±9.2
0–39 yrs 17 (24)
40–49 yrs 23 (33)
50 yrs or older 30 (43)
Childbirth
0 (nullipara) 24 (34)
1 or more 46 (66)
Follow-up periods, mean±SD, months 40±36
Primary tumor size, mean±SD, cm 10.9±11.2
FIGO stage
Stage I 36 (52)
Stage II 5 (7)
Stage III 20 (29)
Stage IV 8 (12)
Associated pathology
Endometriosis 33 (47)
Adenofibroma 6 (9)
Oncologic outcome
Recurrence 4 (3)
Distant metastasis 19 (13)
Cancer-related death 10 (14)
SD, standard deviation; FIGO, International Federation of Gynecology and 
Obstetrics.
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Immunohistochemical profiles of O-CCCs
We analyzed expressional characteristics of several molecules, 
including HNF1β, ERβ, and E-cadherin, along with ARID1A. In 
CCC-associated endometriosis, nuclear staining of ARID1A 
occurs along the epithelial lining, although CCC shows com-
plete loss of ARID1A (Fig. 2A). Fig. 2B-E shows varying degrees 
of ARID1A loss in O-CCC, from total expressional loss (Fig. 2B) 
and focal expression (Fig. 2C) to intact staining (Fig. 2D).
Complete loss of HNF1β was rarely found (5.7%) in O-CCCs 
(Fig. 3A), and most of these O-CCCs were negative for p53 or 
ERβ and loss of ARID1A. In HNF1β-positive cells, HNF1β ex-
pression was higher in cells closer to the luminal side (Fig. 3B). 
Complete loss of ERβ was rare in O-CCCs (Fig. 3C). Luminal 
protruding hobnail cells were positive for ERβ (Fig. 3D). Loss of 
E-cadherin or CDH1 was seen in 21.4% of O-CCCs, and E-cad-
herin loss was variable ranging from complete loss (Fig. 4A and 
B) to aberrant expression, such as fragmentation and broken 
linear forms (Fig. 4C and D) or cytoplasmic staining (Fig. 4E).
Characteristics of ARID1A-negative and 
ARID1A-positive O-CCCs
The expressions of ARID1A “complete loss,” “focal loss,” and “in-
tact” were noted in 48 (66%), 12 (17%), and 10 (14%) cases, re-
spectively. We grouped “focal loss” or “intact” expressions in 
to ARID1A-positive tumors and “complete loss” to ARID1A-
negative tumors. Table 2 compares their clinical and patholog-
ical characteristics. Patient age, parity, tumor size, and distri-
bution of cancer stage were not statistically different between 
ARID1A-negative and positive O-CCCs. In contrast, the ratio of 
histologic high and low grades were significantly different; 
most (90%) of the ARID1A-negative tumors were low grade, 
while 41% of ARID1A-positive tumors were high grade (p=0.003) 
(Table 2). 
Along with this finding, immunohistochemical profiles of 
ARID1A-positive and negative tumors were further analyzed 
(Table 3). To simplify comparisons, the expression status of 
each molecule was categorized as (-) or (+). ARID1A-negative 
tumors exhibited a mostly homogenous expression profile, 
HNF1β-positive (96%), ERβ-negative (83%), and E-cadherin 
positive (83%); whereas ARID1A-positive tumors exhibited 
rather heterogeneous immunohistochemical profiles, HNF1β-
negativity (23%); ERβ-positivity (55%), and E-cadherin loss 
(41%).
Association with oncologic outcomes
To compare cancer-speficic survival, Kaplan-Meier survival 
Fig. 2. ARID1A expressions in O-CCC. (A) In endometriosis, nuclear staining occurs along the epithelial lining (inlet), but CCC shows complete loss of 
ARID1A (DAB, ×40). (B) Total loss of ARID1A in a branched tubular pattern (DAB, ×100). (C) Focal expression (nearly total loss) in an alveolar pattern 
(DAB, ×200). (D) Moderate preservation of AR1D1A expression in a cystic papillary pattern (DAB, ×200). ARID1A, AT-rich DNA-interacting domain 1A; 
O-CCC, clear cell carcinoma of ovary; DAB, 3’-3’ diaminobenzidine.
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curves were generated for ARID1A-positive and negative tu-
mors (Fig. 5). Mean survival times of ARIDA-positive and nega-
tive tumors were 74 months (95% CI 53–95) and 118 months 
(95% CI 105–131) respectively, and the difference was not sta-
tistically significant (p=0.054, log-rank test). 
DISCUSSION
To date, two significant mutational/expressional molecular 
characteristics of O-CCC have been found, ARID1A loss and 
HNF1β-overexpression.2,15 However, their functional roles in 
cancer are still largely unknown, and the relationship between 
those two proteins has not yet been determined. For ARID1A, 
its loss is suggested as a critical event in endometriosis (EM)-
derived O-CCC tumorigenesis.22 Indeed, ARID1A loss has 
been noted in O-CCC associated atypical EM tissues, as well.3 
Since ARID1A is a major component of the human SWI/SNF 
chromatin-remodeling complex,6 its oncogenic role may be re-
lated with remodeling of chromatin and histone re-arrange-
ments4,9,23 or with modulation of estrogenic action.9 We found 
that ARID1A-loss in O-CCC is linked to a specific immunohis-
tochemical profile: ERβ loss, intact E-cadherin, and HNF1β 
overexpression. ERβ expressional loss occurs frequently across 
all epithelial ovarian cancers,24 and ARID1A is important in car-
rying steroid hormone signaling to the SWI/SNF-induced tran-
scriptional activations.12 Since E-cadherin is one of the down-
stream activators of the SWI/SNF complex,14 we initially 
thought that ARID1A loss would accompany E-cadherin loss, 
which turned out to be not true, as ARID1A-lost tumors were 
more-likely to have intact E-cadherin expression than ARID1A-
expressing tumors. This is in contrast with a previous study that 
stated that, in gastric cancer, reduced ARID1A expression 
down-regulates E-cadherin transcription.25 We suspect a hid-
den significance of HNF1β overexpression here.26 The func-
tional role of HNF1β overexpression in O-CCC has not yet 
been derived,15 although it may also be mediated by E-cad-
herin: knock down of HNF1 has been shown to reduce E-cad-
herin expression and promote epithelial-mesenchymal transi-
tion.16 Hypothetically, the uniformly-expressed HNF1β in 
ARID1A-loss tumors in our study might have served a protec-
tive role by maintaining tumor cell E-cadherin expression. 
Thereafter, we argue that this signaling axis, ERβ/ARID1A/E-
cadherin along with HNF1β, requires further molecular func-
tional studies to elucidate the mechanism of O-CCC develop-
ment.
Fig. 3. HNF1β and ERβ expressions in O-CCC. (A and B) HNF1β expression. (A) Complete loss of HNF1-β is rarely found in CCC. However, negative ex-
pression of p53 or ER with loss of ARID1A is common (DAB, ×100). (B) Luminal hobnail cells express HNF1-β. More HNF1-β expression occurs in cells 
closer to the luminal side (DAB, ×200). (C and D) ERβ expression. (C) complete loss of ERβ is common (DAB, ×100). (D) Luminal protruding hobnail 
cells express ERβ (DAB, ×100). ERβ, estrogen receptor beta; O-CCC, clear cell carcinoma of ovary; ARID1A, AT-rich DNA-interacting domain 1A; 
DAB, 3’-3’ diaminobenzidine.
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While ARID1A-negative tumors exhibited a homogenous im-
munoprofile, the immunoprofiles of ARID1A-positive tumor 
were rather heterogeneous: HNF1β-positive rate was slightly 
Using readily available clinical samples and immunohisto-
chemical tools, we sought to characterize ARID1A-negative O-
CCCs in comparison with ARID1A-intact (or positive) O-CCCs. 
Table 2. Clinico-Pathologic Characteristics of ARID1A-Expressing Ovarian Clear Cell Carcinoma 
ARID1A expression, No. (%)
Negative (n=48) Positive (n=22) p value
Age, mean±SD, yrs 47.4±8.8 50.1±9.7 0.162 
Childbirth 0.429 
0 (nullipara) 15 (31) 9 (41)
1 or more 33 (69) 13 (59)
Endometriosis 0.221 
Absent 23 (48) 14 (64)
Present 25 (52) 8 (36)
Primary tumor size, mean±SD, cm 0.976 
Histologic grade 11.0±13.9 10.9±6.0 0.003 
Low grade 43 (90) 13 (59)
High grade 5 (10) 9 (41)
Cancer stage 0.593 
Stage I 26 (55) 10 (46)
Stage II 4 (9) 1 (5)
Stage III 13 (28) 7 (32)
Stage IV 4 (9) 4 (18)
ARID1A, AT-rich DNA-interacting domain 1A. 
t-test for continuous variables, chi-square test for non-continuous variables.
Fig. 4. E-cadherin expressions in O-CCC. Loss of CDH1, or E-cadherin was manifested variably. (A) Complete loss of CDH1 (DAB, ×10). (B) Partial and 
weak staining (DAB, ×100). (C) Aberrant CDH1 expression. Aberrant cytoplasmic expression with fragmented or broken linear forms instead of mem-
brane staining is an indicator of E-cadherin disruption (DAB, ×100). (D) Within the same tumor, CDH1 loss is heterogeneous. The solid arrow points to 
a region of partial CDH1 loss as seen by weak staining along the membrane. The broken arrow points to disrupted fragments in the membrane (DAB, 
×200). (E) Images taken at a higher magnification show aberrant staining, such as and non-continuous, fragmented membrane, or cytoplasmic stain-
ing (DAB, ×200). O-CCC, clear cell carcinoma of ovary; DAB, 3’-3’ diaminobenzidine.
A
D
B C
E
65https://doi.org/10.3349/ymj.2017.58.1.59
Jae Yoon Choi, et al.
low, and the rates of ERβ-negativity and E-cadherin positivity 
were around 50%. Overall, the frequency of ARID1A loss in 
our series was slightly higher (69%) than those of previous 
studies.2,3,20 Nevertheless, this still implies that for about half of 
O-CCC tumors show intact ARID1A, and their tumorigenic pro-
cesses require further explanation.26
HNF1β-overexpression and intact E-cadherin are associated 
with better prognosis in O-CCC,17,27 while the prognostic sig-
nificance of ERβ expression in O-CCC has not been validated. 
The prognostic effect of ARID1A loss in O-CCC is debatable, 
some suggesting a poor prognsosis while others reporting no 
prognostic impacts.17,20,28 In our study, ARID1A expression sta-
tus did not have a significant impact on survival. This indiffer-
ence in survival is noticible since most ARID1A-negative tumors 
in our study were low grade (90%), whereas many of ARID1A-
positive tumors were high grade (41%), and histologic grade is 
directly linked to survival.29 
The human SWI/SNF complex regulates gene transcription 
mainly by modulating DNA methylation status.14 Interestingly, 
O-CCCs is characterized by wide-spread CpG island promoter 
hypermethylation.30 In particular, both HNF and ER pathways 
are frequently methylated in O-CCCs.31,32 Moreover, promoter 
methylation-related expressional changes can lead to disease 
progression in epithelial ovarian cancers. For instance, methyl-
ation status changes result in overexpression of Mucin 13 and 
carbonic anhydrase 9, both of which contribute to aggressive 
behavior of affected cancer cells.33,34 Therefore, it is probable 
that epigenetic dysregulations play a significant role in ARID1A-
negative O-CCC pathophyology, especially if it depends on 
HNF and ER pathways.
In this study, we used a modified two-tier histologic grading 
system based on nuclear atypia and MI. For histological grad-
ing of O-CCC, the Shimizu-Silverberg or the International Fed-
eration of Gynecology and Obstetrics grading systems can be 
used. However, a recent study criticized the significances of both 
systems, which were not effective enough to predict clinical 
outcomes.35 Along with previous reports, our study may provide 
a base for development of further molecular subtyping of O-
CCC, presumably relying on ARID1A expression status.
In conclusion, ARID1A-positive tumors and negative tumors 
differed in gross histology and immunoprofiles. This study 
proposes that ARID1A expression status can be utilized for 
molecular subtyping of O-CCC. Further study is mandatory to 
enlighten the molecular events underlying O-CCC, particular-
ly an ARID1A-independent pathway. 
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